Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
T Yoshida, G Ishii, K Goto, K Yoh, S Niho… - Journal of cancer …, 2013 - Springer
Background The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) differs in patients with lung adenocarcinoma harboring EGFR-activating …
inhibitors (TKIs) differs in patients with lung adenocarcinoma harboring EGFR-activating …
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas
YH Soung, JW Lee, SY Kim, SH Seo, WS Park… - Virchows Archiv, 2005 - Springer
Both epidermal growth factor receptor (EGFR) and RAS gene mutations contribute to the
development of non-small cell lung cancer (NSCLC). Because RAS is one of the …
development of non-small cell lung cancer (NSCLC). Because RAS is one of the …
The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
C Boch, J Kollmeier, A Roth, S Stephan-Falkenau… - BMJ open, 2013 - bmjopen.bmj.com
Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …
[HTML][HTML] The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non–small-cell …
YT Kim, YW Seong, YJ Jung, YK Jeon, IK Park… - Journal of Thoracic …, 2013 - Elsevier
Background The presence of mutation in EGFR gene is known as a predictive marker for the
response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
[HTML][HTML] The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy
C Galvez, S Jacob, BS Finkelman, J Zhao… - Oncotarget, 2020 - ncbi.nlm.nih.gov
Introduction: Roughly one third of new non-small cell lung cancer (NSCLC) is diagnosed at
early stages. While lobectomy can improve mortality in this group, about 30–55% of patients …
early stages. While lobectomy can improve mortality in this group, about 30–55% of patients …
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell …
TY Chou, CH Chiu, LH Li, CY Hsiao, CY Tzen… - Clinical cancer …, 2005 - AACR
Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
[HTML][HTML] Lungs don't forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers
AM Varghese, CS Sima, JE Chaft, ML Johnson… - Journal of Thoracic …, 2013 - Elsevier
Background: We hypothesize that among patients with lung cancers the KRAS/EGFR
mutation profile and overall survival of collegiate smokers (former smokers who smoked …
mutation profile and overall survival of collegiate smokers (former smokers who smoked …
Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis
SM Zhang, QG Zhu, XX Ding, S Lin, J Zhao… - Cancer Management …, 2018 - Taylor & Francis
Background The prognostic value of EGFR and KRAS mutations in resected non-small cell
lung cancer (NSCLC) has been reported. However, conflicting results were reported in these …
lung cancer (NSCLC) has been reported. However, conflicting results were reported in these …
[HTML][HTML] EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
CH Tseng, CJ Chiang, JS Tseng, TY Yang, KH Hsu… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Purpose In the current targeted therapy era, information on the effect of smoking in
epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results In …
epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results In …
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
K Suda, T Mitsudomi - Archives of toxicology, 2015 - Springer
Lung cancers with an epidermal growth factor receptor (EGFR) gene mutation account for~
40% of adenocarcinomas in East Asians and~ 15% of those in Caucasians and African …
40% of adenocarcinomas in East Asians and~ 15% of those in Caucasians and African …